Pomalidomide, bortezomib and dexamethasone in multiple myeloma refractory to lenalidomide and anti-CD38 monoclonal antibodies: outcomes from a real-world experience - PubMed
5 hours ago
- #multiple myeloma
- #real-world outcomes
- #refractory treatment
- Study evaluates pomalidomide, bortezomib, and dexamethasone in multiple myeloma patients refractory to lenalidomide and anti-CD38 monoclonal antibodies.
- Outcomes are derived from a real-world experience, highlighting clinical effectiveness in a challenging patient population.
- Research materials and full-text sources are accessible, though the abstract is not available in the provided text.